Stock Analiz

Corcept Therapeutics Inc. (CORT) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Corcept Therapeutics’s revenue went from $81M in fiscal 2016 to $761M in fiscal 2025, growth of about 28.2% a year.

Net income in fiscal 2025 was $100M, a net margin of 13.1%; the best year in this period was 2024 with $141M.

Over the twelve months to September 30, 2026, revenue was $964M and net income $159M.

Free cash flow was $142M in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count rose 3% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $81M162017: $159M172018: $251M182019: $306M192020: $354M202021: $366M212022: $402M222023: $482M232024: $675M242025: $761M25$761M
Net income
2016: $8M162017: $129M172018: $75M182019: $94M192020: $106M202021: $113M212022: $101M222023: $106M232024: $141M242025: $100M25$100M
Free cash flow
2016: $18M162017: $61M172018: $115M182019: $135M192020: $151M202021: $167M212022: $120M222023: $127M232024: $196M242025: $142M25$142M
EPS (diluted)
2016: $0.07162017: $1.04172018: $0.60182019: $0.77192020: $0.85202021: $0.89212022: $0.87222023: $0.94232024: $1.23242025: $0.8225$0.82

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$964M$761M$675M$482M$402M$366M$354M$306M$251M$159M$81M
Gross profit$950M$748M$664M$476M$396M$361M$348M$301M$246M$156M$79M
Operating income$111M$45M$137M$107M$113M$124M$128M$112M$89M$53M$10M
Net income$159M$100M$141M$106M$101M$113M$106M$94M$75M$129M$8M
EPS (diluted)$1.33$0.82$1.23$0.94$0.87$0.89$0.85$0.77$0.60$1.04$0.07
R&D$242M$255M$247M$184M$131M$114M$115M$89M$75M$40M$24M
Revenue growth—+12.8%+39.9%+20.0%+9.8%+3.4%+15.5%+22.0%+57.8%+95.8%+61.7%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$198M$142M$198M$127M$120M$168M$152M$136M$116M$61M$18M
Capital spending-$3M-$211000-$2M-$139000-$413000-$469000-$1M-$1M-$298000-$419000-$194000
Free cash flow$195M$142M$196M$127M$120M$167M$151M$135M$115M$61M$18M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$6M$173M$16M$0$0—$10M$31M$24M$0$0
Stock-based pay$103M$84M$61M$49M$42M$43M$34M$29M$24M$13M$7M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$372M$383M$368M$432M$224M$441M$276M$207M$89M$52M
Debt—$6M$7M$151000$1M$526000$3M$3M—$0$15M
Equity—$648M$680M$507M$502M$376M$523M$371M$276M$191M$41M
Total assets—$837M$841M$622M$583M$424M$572M$412M$312M$221M$69M
Shares (diluted)123M120M113M112M116M126M124M123M127M125M116M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin98.5%98.3%98.4%98.7%98.7%98.6%98.4%98.2%97.9%97.8%97.5%
Operating margin11.5%5.9%20.3%22.2%28.0%34.0%36.2%36.4%35.6%33.2%12.5%
Net margin16.5%13.1%20.9%22.0%25.2%30.7%30.0%30.7%30.0%81.1%10.0%
FCF margin20.2%18.6%29.0%26.2%29.8%45.8%42.6%44.1%45.9%38.0%22.4%
ROIC—5.4%17.4%18.0%19.6%29.8%19.6%24.1%26.6%21.9%18.2%
ROE—15.4%20.8%20.9%20.2%29.9%20.3%25.4%27.3%67.6%19.7%

Frequently asked questions

What is Corcept Therapeutics’s annual revenue?

$761M in fiscal 2025 and $964M over the twelve months to September 30, 2026.

How much profit does Corcept Therapeutics make?

Net income was $100M in fiscal 2025 (net margin 13.1%).

Is Corcept Therapeutics’s revenue growing?

Yes: revenue rose 12.8% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.